Alba Rubio-San-Simón

15PUBLICATIONS
118CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 25, 2026
Impact of Metastatic Patterns on Survival and Response to Therapy in Neuroblastoma.

|Jan 27, 2026
Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

Susanne A Gatz, Pablo Berlanga, Gwénaël Le Teuff

|Dec 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Juliet C Gray, Rebekah Weston, Cormac Owens

|Dec 11, 2025
Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study.

Alba Rubio-San-Simón, Lynley V Marshall, Francois Doz

|Aug 18, 2025
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials.

Emanuela Palmerini, Cristina Meazza, Angela Tamburini

|Jul 29, 2025
Prognostic factors in patients with relapsed high-grade osteosarcoma: a systematic review.

Alba Rubio-San-Simón, William Wilson, Giovanna Sironi

Pageof 3

Frequent Collaborators

7 joint publications

Lucas Moreno

5 joint publications

Francisco Bautista

4 joint publications

Ricardo López-Almaraz

4 joint publications

Adela Cañete